FDCP
GSK icon

Foster Dykema Cabot & Partners’s GSK GSK Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40
Closed -$1.73K – 372
2025
Q3 		$1.73K Buy
+40
New +$1.56K ﹤0.01% 399
2024
Q4 		– Sell
-1,160
Closed -$47.9K – 423
2024
Q3 		$47.9K Hold
1,160
– – ﹤0.01% 225
2024
Q2 		$45.1K Hold
1,160
– – ﹤0.01% 182
2024
Q1 		$50.2K Hold
1,160
– – ﹤0.01% 179
2023
Q4 		$43.4K Buy
+1,160
New +$41.6K ﹤0.01% 160

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Foster Dykema Cabot & Partners's GSK Position: Q4 2025 in Review

Foster Dykema Cabot & Partners sold out of GSK (GSK) in Q4 2025, closing a stake of 40 shares — an estimated $1.73K sold.

Foster Dykema Cabot & Partners first reported a position in GSK in Q4 2023 and held it in 5 quarters. The position peaked at $50.2K in Q1 2024. 995 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

  • Foster Dykema Cabot & Partners reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
  • Foster Dykema Cabot & Partners sold 40 GSK shares in Q4 2025, an estimated $1.73K.
  • Foster Dykema Cabot & Partners first reported a position in GSK in Q4 2023 and held it in 5 quarters.
  • Foster Dykema Cabot & Partners's GSK position peaked at $50.2K in Q1 2024.
  • 995 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Foster Dykema Cabot & Partners's 13F filing for Q4 2025, filed 12 Feb 2026.